• Je něco špatně v tomto záznamu ?

Dual-Tracer PET-MRI-Derived Imaging Biomarkers for Prediction of Clinically Significant Prostate Cancer

B. Grubmüller, NA. Huebner, S. Rasul, P. Clauser, N. Pötsch, KH. Grubmüller, M. Hacker, S. Hartenbach, SF. Shariat, M. Hartenbach, P. Baltzer

. 2023 ; 30 (2) : 1683-1691. [pub] 20230130

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23004487

PURPOSE: To investigate if imaging biomarkers derived from 3-Tesla dual-tracer [(18)F]fluoromethylcholine (FMC) and [68Ga]Ga-PSMAHBED-CC conjugate 11 (PSMA)-positron emission tomography can adequately predict clinically significant prostate cancer (csPC). METHODS: We assessed 77 biopsy-proven PC patients who underwent 3T dual-tracer PET/mpMRI followed by radical prostatectomy (RP) between 2014 and 2017. We performed a retrospective lesion-based analysis of all cancer foci and compared it to whole-mount histopathology of the RP specimen. The primary aim was to investigate the pretherapeutic role of the imaging biomarkers FMC- and PSMA-maximum standardized uptake values (SUVmax) for the prediction of csPC and to compare it to the mpMRI-methods and PI-RADS score. RESULTS: Overall, we identified 104 cancer foci, 69 were clinically significant (66.3%) and 35 were clinically insignificant (33.7%). We found that the combined FMC+PSMA SUVmax were the only significant parameters (p < 0.001 and p = 0.049) for the prediction of csPC. ROC analysis showed an AUC for the prediction of csPC of 0.695 for PI-RADS scoring (95% CI 0.591 to 0.786), 0.792 for FMC SUVmax (95% CI 0.696 to 0.869), 0.852 for FMC+PSMA SUVmax (95% CI 0.764 to 0.917), and 0.852 for the multivariable CHAID model (95% CI 0.763 to 0.916). Comparing the AUCs, we found that FMC+PSMA SUVmax and the multivariable model were significantly more accurate for the prediction of csPC compared to PI-RADS scoring (p = 0.0123, p = 0.0253, respectively). CONCLUSIONS: Combined FMC+PSMA SUVmax seems to be a reliable parameter for the prediction of csPC and might overcome the limitations of PI-RADS scoring. Further prospective studies are necessary to confirm these promising preliminary results.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23004487
003      
CZ-PrNML
005      
20230425141436.0
007      
ta
008      
230418s2023 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/curroncol30020129 $2 doi
035    __
$a (PubMed)36826090
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Grubmüller, Bernhard $u Department of Urology, Medical University of Vienna, 1090 Vienna, Austria $u Department of Urology and Andrology, University Hospital Krems, 3500 Krems, Austria $u Karl Landsteiner University of Health Sciences, 3500 Krems, Austria $u Working Group of Diagnostic Imaging in Urology, Austrian Society of Urology, 1090 Vienna, Austria
245    10
$a Dual-Tracer PET-MRI-Derived Imaging Biomarkers for Prediction of Clinically Significant Prostate Cancer / $c B. Grubmüller, NA. Huebner, S. Rasul, P. Clauser, N. Pötsch, KH. Grubmüller, M. Hacker, S. Hartenbach, SF. Shariat, M. Hartenbach, P. Baltzer
520    9_
$a PURPOSE: To investigate if imaging biomarkers derived from 3-Tesla dual-tracer [(18)F]fluoromethylcholine (FMC) and [68Ga]Ga-PSMAHBED-CC conjugate 11 (PSMA)-positron emission tomography can adequately predict clinically significant prostate cancer (csPC). METHODS: We assessed 77 biopsy-proven PC patients who underwent 3T dual-tracer PET/mpMRI followed by radical prostatectomy (RP) between 2014 and 2017. We performed a retrospective lesion-based analysis of all cancer foci and compared it to whole-mount histopathology of the RP specimen. The primary aim was to investigate the pretherapeutic role of the imaging biomarkers FMC- and PSMA-maximum standardized uptake values (SUVmax) for the prediction of csPC and to compare it to the mpMRI-methods and PI-RADS score. RESULTS: Overall, we identified 104 cancer foci, 69 were clinically significant (66.3%) and 35 were clinically insignificant (33.7%). We found that the combined FMC+PSMA SUVmax were the only significant parameters (p < 0.001 and p = 0.049) for the prediction of csPC. ROC analysis showed an AUC for the prediction of csPC of 0.695 for PI-RADS scoring (95% CI 0.591 to 0.786), 0.792 for FMC SUVmax (95% CI 0.696 to 0.869), 0.852 for FMC+PSMA SUVmax (95% CI 0.764 to 0.917), and 0.852 for the multivariable CHAID model (95% CI 0.763 to 0.916). Comparing the AUCs, we found that FMC+PSMA SUVmax and the multivariable model were significantly more accurate for the prediction of csPC compared to PI-RADS scoring (p = 0.0123, p = 0.0253, respectively). CONCLUSIONS: Combined FMC+PSMA SUVmax seems to be a reliable parameter for the prediction of csPC and might overcome the limitations of PI-RADS scoring. Further prospective studies are necessary to confirm these promising preliminary results.
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé $7 D006801
650    12
$a nádory prostaty $x patologie $7 D011471
650    _2
$a magnetická rezonanční tomografie $7 D008279
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a prospektivní studie $7 D011446
650    _2
$a PET/CT $x metody $7 D000072078
650    _2
$a pozitronová emisní tomografie $7 D049268
655    _2
$a časopisecké články $7 D016428
700    1_
$a Huebner, Nicolai A $u Department of Urology, Medical University of Vienna, 1090 Vienna, Austria $u Working Group of Diagnostic Imaging in Urology, Austrian Society of Urology, 1090 Vienna, Austria
700    1_
$a Rasul, Sazan $u Department of Biomedical Imaging and Image Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, 1090 Vienna, Austria $1 https://orcid.org/0000000328983232
700    1_
$a Clauser, Paola $u Department of Biomedical Imaging and Image Guided Therapy, Division of General and Pediatric Radiology, Medical University of Vienna, 1090 Vienna, Austria
700    1_
$a Pötsch, Nina $u Department of Biomedical Imaging and Image Guided Therapy, Division of General and Pediatric Radiology, Medical University of Vienna, 1090 Vienna, Austria
700    1_
$a Grubmüller, Karl Hermann $u Department of Urology and Andrology, University Hospital Krems, 3500 Krems, Austria $u Karl Landsteiner University of Health Sciences, 3500 Krems, Austria
700    1_
$a Hacker, Marcus $u Department of Biomedical Imaging and Image Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, 1090 Vienna, Austria $1 https://orcid.org/0000000242224083
700    1_
$a Hartenbach, Sabrina $u HistoConsultingHartenbach, 89081 Ulm, Germany
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Medical University of Vienna, 1090 Vienna, Austria $u Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria $u Department of Urology, Weill Medical College of Cornell University, New York, NY 10021, USA $u Department of Urology, University of Texas Southwestern, Dallas, TX 75390, USA $u Department of Urology, Second Faculty of Medicine, Charles University, 116 36 Prague, Czech Republic $u Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman 19328, Jordan $u Karl Landsteiner Institute of Urology and Andrology, 1010 Vienna, Austria
700    1_
$a Hartenbach, Markus $u Department of Biomedical Imaging and Image Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, 1090 Vienna, Austria
700    1_
$a Baltzer, Pascal $u Department of Biomedical Imaging and Image Guided Therapy, Division of General and Pediatric Radiology, Medical University of Vienna, 1090 Vienna, Austria
773    0_
$w MED00165427 $t Current oncology (Toronto, Ont.) $x 1718-7729 $g Roč. 30, č. 2 (2023), s. 1683-1691
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36826090 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425141432 $b ABA008
999    __
$a ok $b bmc $g 1924908 $s 1190696
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 30 $c 2 $d 1683-1691 $e 20230130 $i 1718-7729 $m Current oncology $n Curr. oncol. $x MED00165427
LZP    __
$a Pubmed-20230418

Najít záznam

Citační ukazatele

Možnosti archivace